# EDGAR Filing Document

**Accession Number:** 0001000753
**File Stem:** 0001000753-25-000104
**Filing Date:** 2025-11
**Character Count:** 51579
**Document Hash:** 5f138fc19174e7cf16cb011f6a5850c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001000753-25-000104.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001000753-25-000104

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20251103

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INSPERITY, INC.
- **CENTRAL INDEX KEY:** 0001000753
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HELP SUPPLY SERVICES [7363]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 760479645
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13998
- **FILM NUMBER:** 251444845

**BUSINESS ADDRESS:**
- **STREET 1:** 19001 CRESCENT SPRINGS DR
- **CITY:** KINGWOOD
- **STATE:** TX
- **ZIP:** 77339
- **BUSINESS PHONE:** 7133588986

**MAIL ADDRESS:**
- **STREET 1:** 19001 CRESCENT SPRINGS DR
- **CITY:** KINGWOOD
- **STATE:** TX
- **ZIP:** 77339

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADMINISTAFF INC \DE\
- **DATE OF NAME CHANGE:** 19950915

?xml version='1.0' encoding='ASCII'? nsp-20251103

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): November 3, 2025

**Insperity, Inc.** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-13998** | **76-0479645** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**19001 Crescent Springs Drive** 

**Kingwood**, **Texas 77339**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(281) 358-8986** 

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Ticker symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $.01 par value per share** | **NSP** | **New York Stock Exchange** |
|  |  | **NYSE Texas** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under The Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under The Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.01. Entry into a Material Definitive Agreement.**

On November 3, 2025, a subsidiary of Insperity, Inc. (the "Company") entered into an amendment to its arrangement with UnitedHealthcare related to its medical coverage (the "Amendment"). The Amendment includes additional expected cost savings starting in 2026 and extends the arrangement through 2028; provides the Company with the option to annually elect to limit its responsibility for each participant's claim costs to $500,000, $750,000, or $1,000,000 per year; revises certain administrative costs payable by the Company; and adds additional volume-based incentives, subject to certain conditions. The other previously disclosed material items remain unchanged. The foregoing summary is qualified in its entirety by reference to the agreement, a copy of which is filed as Exhibit 10.1 to this Form 8-K and is incorporated in this Item 1.01 by reference.

A copy of the Company's press release announcing this amendment is attached as Exhibit 99.1.

**Item 2.02. Results of Operations and Financial Condition.**

On November 3, 2025, Insperity, Inc. issued a press release announcing the company's financial and operating results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| 10.1 | (+) | <u>[Letter Agreement by and between Insperity Holdings, Inc. and UnitedHealthcare Insurance Company entered into as of November 3, 2025.](a09302025-ex1012026insperi.htm)</u> |
| 99.1 |  | <u>[Press release regarding financial and operating results issued by Insperity, Inc. on November 3, 2025.](a09302025-ex991earningsrel.htm)</u> |
| 104 |  | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
|  | (+) | Certain portions of the exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) the type of information the Company treats as private or confidential. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| INSPERITY, INC. | INSPERITY, INC. |
| By: | */s/ Christian P. Callens* |
|  | Christian P. Callens |
|  | Senior Vice President of Legal, <br>General Counsel & Secretary |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Date: November 3, 2025

## Exhibit 10.1

*Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) the type of information that the Company treats as private or confidential.*

**Exhibit 10.1**

![image_0.jpg](image_0.jpg)

November 2, 2025&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Mr. James D. Allison

CFO, Insperity Holdings, Inc.

19001 Crescent Springs Drive

Kingwood, TX 77339

Re: 2026 Insperity and UnitedHealthcare Health Agreement Extension

Dear Jim:

UnitedHealthcare is very pleased to provide Insperity with this Letter of Agreement which includes the proposed modifications to the existing contracts between UnitedHealthcare Insurance Company ("UnitedHealthcare") and Insperity Holdings, Inc. ("Insperity").

Upon execution, this Letter of Agreement and the attached Exhibit A will constitute a legally binding agreement as to the principal terms of amendments to the Minimum Premium Financial Agreement and the Minimum Premium Administrative Services Agreement, each by and between Insperity and UnitedHealthcare, as amended and restated from time to time (collectively, the "Medical Definitive Agreements"). The parties agree that such Amendments shall be prepared and executed as soon as possible.

Except as otherwise set forth herein, the terms and conditions of any eventual modifications to the Medical Definitive Agreements will be only as set forth in any subsequent amendment(s) signed by the parties.

Insperity and UnitedHealthcare acknowledge and agree that the terms and conditions of this letter and the attached Exhibit A relating to the Medical Agreements, including the existence thereof, are subject to the provisions of Section 5(e) of the Minimum Premium Administrative Services Agreement (relating to publicity of the arrangement). As such, Insperity and UnitedHealthcare each agree not to make any unauthorized disclosure or public announcement concerning the subject matter thereof without the written consent of the other except to the extent required by law.

On behalf of UnitedHealthcare and the members that we are honored to serve with Insperity, I thank you yet again Jim for the many years of support and consideration between our two organizations.

If this Letter of Agreement and the terms set forth in Exhibit A are in accordance with your understanding of the proposed modifications to our existing contracts, please sign below and return an executed copy to me. Should you have any questions, please call me at ([ ]) [ ].

Best Regards,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| AGREED TO AND ACCEPTED BY: | |
| /s/ Anthony R. Carr | /s/ James D. Allison |
| Anthony R. Carr | James D. Allison |
| National Vice President | CFO |
| UnitedHealthcare | Insperity Holdings, Inc. |
| | Date: November 3, 2025 |

---

------

------

**Exhibit A**

**UnitedHealthcare/Insperity**

**Terms of Agreement**

For consistency, clarity and ease of communication, this Exhibit A uses certain defined terms from the Medical Definitive Agreements between Insperity and UnitedHealthcare (UHC) (together the "Parties"), the provisions of which are hereby amended effective January 1, 2026, unless otherwise indicated.

As part of this Exhibit A, the Parties desire to modify the Medical Definitive Agreements, including to extend the term of the agreement until December 31, 2028. The Parties have also agreed to [ ] the [ ] (see below), for the duration of the revised agreement.

1)&nbsp;&nbsp;&nbsp;&nbsp;For avoidance of doubt, the [ ] previously agreed to in the Medical Definitive Agreements by the Parties remain unchanged.

2)&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that the UnitedHealthcare [ ] shall be as follows:

---

| | | | |
|:---|:---|:---|:---|
| | 2026 | 2027 | 2028 |
| [ ] | [ ] | [ ] | [ ] |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;UnitedHealthcare shall provide the following [ ] on a trailing quarterly basis to Insperity per specified [ ], on each occasion such a [ ] is [ ], as follows:

---

| | | | |
|:---|:---|:---|:---|
| | 2026 | 2027 | 2028 |
| [ ] | [ ] | [ ] | [ ] |
| [ ] | [ ] | [ ] | [ ] |
| [ ] | [ ] | [ ] | [ ] |

---

The amounts set forth above for 2027 and 2028 are [ ] to be applied following the annual update of the [ ] applicable to Insperity and standard fully-insured large group UnitedHealthcare customers in the states where Insperity's plans are sitused. The Parties agree that the [ ] set forth above for 2027 and 2028 will be [ ] as necessary to [ ] with [ ] as negotiated by the Parties in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;UnitedHealthcare will continue the "[ ]", as such term is defined in the letter agreement dated March 26, 2025 between the Parties (March 2025 LOA) for each "[ ]" covered for health insurance ([ ]) under the Medical Definitive Agreements. For avoidance of doubt, the [ ] of the [ ] and the years corresponding to the dates specified in the March 2025 LOA shall be adjusted to reflect the years specified below, and the other terms applicable to the [ ].

---

| | | | |
|:---|:---|:---|:---|
| | 2026 | 2027 | 2028 |
| [ ] | [ ] | [ ] | [ ] |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;The [ ] and [ ] portion payable to UnitedHealthcare shall [ ] at [ ].

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e)&nbsp;&nbsp;&nbsp;&nbsp;The pooling feature will continue to be made available as an option to Insperity for the 2026, 2027 and 2028 calendar years at the following attachment levels and charges:

---

| | | | |
|:---|:---|:---|:---|
| **Pooling Level** | **2026** | **2027** | **2028** |
| $1 million | [ ] | [ ] | [ ] |
| $750000 | [ ] | [ ] | [ ] |
| $500000 | [ ] | [ ] | [ ] |

---

The decision to accept the pooling feature and at what level shall be made by Insperity no later than December 31st each year.

\* The Parties agree that the [ ] for 2027 and 2028 [ ] set based on [ ], with no [ ] in [ ] of UnitedHealthcare's [ ], plus any applicable [ ] associated with the pooling feature, as [ ] by the Parties in good faith, with [ ] delivery no later than October 15 each year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f)&nbsp;&nbsp;&nbsp;&nbsp;In the event of fundamental regulatory or [ ] changes that materially alter the financial structure of the [ ] of [ ] subject to [ ] under Section 2(b) of this Exhibit A to the letter agreement, the Parties agree to mutually negotiate in good faith changes to this Exhibit A with no less than a [ ] notice requirement from UnitedHealthcare before any changes are implemented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g)&nbsp;&nbsp;&nbsp;&nbsp;The [ ] credit is earned for calendar year 2025 and will be paid by UnitedHealthcare to Insperity in 2026 but shall be eliminated for future years.

## Exhibit 99.1

**Exhibit 99.1**

**Insperity Announces Third Quarter Results and** 

**New UnitedHealthcare Contract**

HOUSTON – November 3, 2025 – Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for America's best businesses, today reported results for the third quarter ended September 30, 2025. Insperity will be hosting a conference call today at 5:00 p.m. ET to discuss these results, our updated 2025 outlook, and perspectives on expected 2026 key drivers of growth and profitability. We will be posting an accompanying presentation to our investor website at http://ir.insperity.com.

&nbsp;&nbsp;&nbsp;&nbsp;• Q3 revenues up 4% year-over-year

&nbsp;&nbsp;&nbsp;&nbsp;• Q3 average paid WSEEs up 1% to 312,842

&nbsp;&nbsp;&nbsp;&nbsp;• Q3 net loss of $20 million; adjusted EBITDA of $10 million

&nbsp;&nbsp;&nbsp;&nbsp;• Q3 diluted EPS of $(0.53); adjusted EPS of $(0.20)

&nbsp;&nbsp;&nbsp;&nbsp;• YTD average paid WSEEs up 1% to 309,327

&nbsp;&nbsp;&nbsp;&nbsp;• YTD net income of $26 million; adjusted EBITDA of $144 million

&nbsp;&nbsp;&nbsp;&nbsp;• YTD diluted EPS of $0.69; adjusted EPS of $1.63

&nbsp;&nbsp;&nbsp;&nbsp;• Return to shareholders of $87 million during the first nine months of 2025 through the repurchase of 225,000 shares at a cost of $19 million and $68 million in cash dividends

&nbsp;&nbsp;&nbsp;&nbsp;• UHC contract extended through 2028 providing significant cost savings, lower risk, and strategic alignment

&nbsp;&nbsp;&nbsp;&nbsp;• HRScale (Insperity/Workday joint solution) product rollout underway

**Third Quarter Results**

"We are actively working to position Insperity for sustainable profitability at normal historical levels as we execute on our plan in response to unexpected, elevated healthcare cost trend. We are simultaneously taking assertive actions, including through the new contract with UnitedHealthcare, and will continue to focus on attracting and retaining the right clients at the right price and prudently managing expenses," said Paul J. Sarvadi, Insperity chairman and chief executive officer. "We are also pleased to announce the official rollout of HRScale, our strategic joint development offering with Workday. We believe this offering will position Insperity uniquely within the marketplace and serve as a catalyst for future growth. While we are making progress in the areas we can control, the macro pressures affecting our business remain significant and we recognize there is more work to do to deliver the results we know Insperity can produce."

The average number of worksite employees ("WSEE") paid per month increased 1% from Q3 2024 to 312,842 WSEEs. Revenues in Q3 2025 increased 4% to $1.6 billion on a 3% increase in revenue per WSEE on higher pricing and the increase in paid WSEEs.

Gross profit decreased 15% to $195 million in Q3 2025 from $229 million in Q3 2024 due primarily to higher-than-expected benefits costs. Higher Q3 2025 healthcare costs were driven by elevated inpatient, outpatient and pharmacy trends and frequency of large claim activity.

"We are pleased to announce a multi-year contract extension with UnitedHealthcare which provides significant cost reductions and reduces our pooling level for large claims to $500,000 beginning on January 1, 2026. We expect these changes will provide outstanding value for plan participants and help address the challenging employee benefits cost trend environment," said James D. Allison, executive vice president of finance, chief financial officer and treasurer. "We believe the structure of the agreement improves our financial outlook substantially for 2026 and enhances strategic alignment for growth and profitability in subsequent years."

Operating expenses decreased 4% to $220 million in Q3 2025 from $228 million in Q3 2024. Operating expenses included $11 million and $19 million for our Workday strategic partnership in Q3 2025 and Q3 2024, respectively.

------

Reported net loss was $20 million and diluted EPS was $(0.53). Adjusted EBITDA and adjusted EPS were $10 million and $(0.20), respectively.

**Year-to-Date Results**

The average number of WSEEs paid per month increased 1% from 2024 to 309,327 WSEEs. Revenues increased by 4% to $5.1 billion on a 3% increase in revenue per WSEE and the increase in paid WSEEs.

Gross profit decreased 13% to $728 million primarily due to unfavorable results from our benefits costs program, offset in part by increased pricing and favorability in other direct cost areas.

Operating expenses declined 1% to $692 million as compared to the 2024 period. Operating expenses included $38 million for our Workday strategic partnership in YTD 2025.

Reported net income and diluted EPS were $26 million and $0.69, respectively. Adjusted EBITDA and adjusted EPS were $144 million and $1.63, respectively.

Cash outlays in the first nine months of 2025 included the repurchase of approximately 225,000 shares of our common stock at a cost of $19 million, dividends totaling $68 million, and capital expenditures of $22 million. Adjusted cash at September 30, 2025 totaled $120 million and we had outstanding borrowings of $370 million under our $650 million credit facility.

**2025 Guidance**

The company also announced its updated guidance for 2025, including the fourth quarter of 2025. Please refer to the accompanying financial tables at the end of this press release for the reconciliation of non-GAAP financial measures to the comparable GAAP financial measures.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Q4 2025** | **Q4 2025** | **Full Year 2025** | **Full Year 2025** |
| Average WSEEs paid | 313000 | 315000 | 310200 | 310700 |
| Year-over-year increase | 1.3% | 1.9% | 1.0% | 1.1% |
| Adjusted EPS | $(0.79) | $(0.16) | $0.84 | $1.47 |
| Year-over-year decrease |  |  | (77)% | (59)% |
| Adjusted EBITDA (in millions) | $(25) | $9 | $119 | $153 |
| Year-over-year decrease | (209)% | (61)% | (56)% | (43)% |

---

***Definition of Key Metrics***

Average WSEEs paid — Determined by calculating the company's cumulative WSEEs paid during the period divided by the number of months in the period.

Adjusted EPS — Represents diluted net income per share computed in accordance with GAAP, excluding the impact of non-cash stock-based compensation.

Adjusted EBITDA — Represents net income computed in accordance with GAAP, plus interest expense, income taxes, depreciation and amortization expense, amortization of SaaS implementation costs and non-cash stock-based compensation.

**Conference Call and Webcast**

Insperity will be hosting a conference call today at 5:00 p.m. ET to discuss these results and the guidance discussed in this press release, and answer questions from investment analysts. To listen in, call 888-506-0062 and use conference i.d. number 663681. The call will also be webcast at http://ir.insperity.com. The conference call script will be available at the same website later today. A replay of the conference call will be available at 877-481-4010, conference i.d. number 53083. The webcast will be archived for one year.

------

**About Insperity**

Since 1986, Insperity's mission has been to help businesses succeed so communities prosper. Offering a suite of the most comprehensive, scalable HR solutions available in the marketplace, Insperity is defined by an unrivaled breadth and depth of services and level of care. Through an optimal blend of premium HR service and technology, Insperity delivers the administrative relief, reduced liabilities and better benefit solutions that businesses need to drive performance and growth. With 2024 revenues of $6.6 billion and more than 90 sales offices throughout the U.S., Insperity is currently making a difference in thousands of businesses and communities nationwide. For more information, visit http://www.insperity.com.

**Forward-Looking Statements**

The statements contained herein that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify such forward-looking statements by the words "anticipates," "expects," "intends," "plans," "projects," "believes," "estimates," "forecasts," "likely," "possibly," "probably," "could," "goal," "opportunity," "objective," "target," "assume," "outlook," "guidance," "predicts," "appears," "indicator" and similar expressions. Forward-looking statements involve a number of risks and uncertainties. In the normal course of business, in an effort to help keep our stockholders and the public informed about our operations, from time to time, we may issue such forward-looking statements, either orally or in writing. Generally, these statements relate to business plans or strategies, including our strategic partnership with Workday, Inc.; projected or anticipated benefits or other consequences of such plans or strategies; or projections involving anticipated revenues, earnings, average number of worksite employees, benefits and workers' compensation costs, or other operating results. We base these forward-looking statements on our current expectations, estimates and projections. We caution you that these statements are not guarantees of future performance and involve risks, uncertainties and assumptions that we cannot predict. In addition, we have based many of these forward-looking statements on assumptions about future events that may prove to be inaccurate. Therefore, the actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements. Among the factors that could cause actual results to differ materially are:

&nbsp;&nbsp;&nbsp;&nbsp;• adverse economic conditions;

&nbsp;&nbsp;&nbsp;&nbsp;• failure to comply with or meet client expectations regarding certain COVID-19 relief programs, including the federal employee retention tax credit program;

&nbsp;&nbsp;&nbsp;&nbsp;• bank failures or other events affecting financial institutions;

&nbsp;&nbsp;&nbsp;&nbsp;• labor shortages, increasing competition for highly skilled workers, and evolving employee expectations regarding the workplace;

&nbsp;&nbsp;&nbsp;&nbsp;• impact of inflation and changes in U.S. trade policy;

&nbsp;&nbsp;&nbsp;&nbsp;• vulnerability to regional economic factors because of our geographic market concentration;

&nbsp;&nbsp;&nbsp;&nbsp;• failure to comply with covenants under our credit facility;

&nbsp;&nbsp;&nbsp;&nbsp;• impact of a future outbreak of highly infectious or contagious disease;

&nbsp;&nbsp;&nbsp;&nbsp;• our liability for WSEE payroll, payroll taxes and benefits costs, or other liabilities associated with actions of our client companies or WSEEs, including if our clients fail to pay us;

&nbsp;&nbsp;&nbsp;&nbsp;• increases in health insurance costs and workers' compensation rates and underlying claims trends, health care reform, financial solvency of workers' compensation carriers, other insurers or financial institutions, state unemployment tax rates, liabilities for employee and client actions or payroll-related claims;

&nbsp;&nbsp;&nbsp;&nbsp;• an adverse determination regarding our status as the employer of our WSEEs for tax and benefit purposes and an inability to offer alternative benefit plans following such a determination;

&nbsp;&nbsp;&nbsp;&nbsp;• cancellation of client contracts on short notice, or the inability to renew client contracts or attract new clients;

&nbsp;&nbsp;&nbsp;&nbsp;• the ability to secure competitive replacement contracts for health insurance and workers' compensation insurance at expiration of current contracts;

&nbsp;&nbsp;&nbsp;&nbsp;• regulatory and tax developments and possible adverse application of various federal, state and local regulations;

&nbsp;&nbsp;&nbsp;&nbsp;• failure to manage growth of our operations and the effectiveness of our sales and marketing efforts;

&nbsp;&nbsp;&nbsp;&nbsp;• the impact of the competitive environment and other developments in the human resources services industry, including the professional employer organization (or PEO) industry, on our growth and/or profitability;

&nbsp;&nbsp;&nbsp;&nbsp;• an adverse final judgment or settlement of claims against Insperity;

&nbsp;&nbsp;&nbsp;&nbsp;• disruptions of our information technology systems or failure to enhance our service and technology offerings to address new regulations or client expectations;

&nbsp;&nbsp;&nbsp;&nbsp;• our liability or damage to our reputation relating to disclosure of sensitive or private information as a result of data theft, cyberattacks or security vulnerabilities;

&nbsp;&nbsp;&nbsp;&nbsp;• failure of third-party providers, such as financial institutions, data centers or cloud service providers;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to fully realize the anticipated benefits of our strategic partnership and joint solution with Workday, Inc.; and

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to integrate or realize expected returns on future product offerings, including through acquisitions, strategic partnerships, and investments.

These factors are discussed in further detail in Insperity's filings with the U.S. Securities and Exchange Commission. Any of these factors, or a combination of such factors, could materially affect the results of our operations and whether forward-looking statements we make ultimately prove to be accurate.

Any forward-looking statements are made only as of the date hereof and, unless otherwise required by applicable securities laws, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

------

**SUMMARY FINANCIAL INFORMATION**<br>

**Insperity, Inc.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
| *(Unaudited)* | **September 30, 2025** | **December 31, 2024** |
| *(in millions)* | **September 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $422 | $1039 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 79 | 69 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 18 | 16 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 894 | 829 |
| &nbsp;&nbsp;&nbsp;Prepaid insurance and related assets | 17 | 25 |
| &nbsp;&nbsp;&nbsp;Income taxes receivable | 35 |  |
| &nbsp;&nbsp;&nbsp;Other current assets | 89 | 107 |
| **Total current assets** | **1554** | **2085** |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 180 | 192 |
| &nbsp;&nbsp;&nbsp;Right-of-use leased assets | 65 | 65 |
| &nbsp;&nbsp;&nbsp;Deposits and prepaid health insurance | 164 | 195 |
| &nbsp;&nbsp;&nbsp;Goodwill and other intangible assets, net | 13 | 13 |
| &nbsp;&nbsp;&nbsp;Deferred income taxes, net | 3 | 34 |
| &nbsp;&nbsp;&nbsp;Other assets | 33 | 13 |
| **Total assets** | $**2012** | $**2597** |
| **Liabilities and stockholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $8 | $10 |
| &nbsp;&nbsp;&nbsp;Payroll taxes and other payroll deductions payable | 334 | 901 |
| &nbsp;&nbsp;&nbsp;Accrued worksite employee payroll cost | 774 | 730 |
| &nbsp;&nbsp;&nbsp;Accrued health insurance costs | 31 | 19 |
| &nbsp;&nbsp;&nbsp;Accrued workers' compensation costs | 81 | 71 |
| &nbsp;&nbsp;&nbsp;Accrued corporate payroll and commissions | 74 | 82 |
| &nbsp;&nbsp;&nbsp;Other accrued liabilities | 80 | 117 |
| **Total current liabilities** | **1382** | **1930** |
| &nbsp;&nbsp;&nbsp;Accrued workers' compensation costs, net of current | 107 | 135 |
| &nbsp;&nbsp;&nbsp;Long-term debt | 369 | 369 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current | 67 | 66 |
| **Total noncurrent liabilities** | **543** | **570** |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 244 | 222 |
| &nbsp;&nbsp;&nbsp;Treasury stock, at cost | (852) | (864) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 694 | 738 |
| **Total stockholders' equity** | **87** | **97** |
| **Total liabilities and stockholders' equity** | $**2012** | $**2597** |

---

------

**SUMMARY FINANCIAL INFORMATION**<br>

**Insperity, Inc.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(Unaudited)* | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| *(in millions, except per share amounts)* | **2025** | **2024** | **Change** | **2025** | **2024** | **Change** |
| Operating results: |  |  |  |  |  |  |
| **Revenues**<sup>(1)</sup> | $**1623** | $**1561** | **4%** | $**5144** | $**4968** | **4%** |
| Payroll taxes, benefits and workers' compensation costs | 1428 | 1332 | 7% | 4416 | 4134 | 7% |
| **Gross profit** | **195** | **229** | **(15)%** | **728** | **834** | **(13)%** |
| Salaries, wages and payroll taxes | 125 | 127 | (2)% | 396 | 393 | 1% |
| Stock-based compensation | 16 | 17 | (6)% | 47 | 47 |  |
| Commissions | 13 | 11 | 18% | 34 | 34 |  |
| Advertising | 10 | 9 | 11% | 28 | 28 |  |
| General and administrative expenses | 45 | 53 | (15)% | 154 | 167 | (8)% |
| Depreciation and amortization | 11 | 11 |  | 33 | 33 |  |
| **Total operating expenses** | **220** | **228** | **(4)%** | **692** | **702** | **(1)%** |
| **Operating income (loss)** | **(25)** | **1** | **—** | **36** | **132** | **(73)%** |
| Other income (expense): |  |  |  |  |  |  |
| &nbsp;&nbsp;Interest income | 7 | 9 | (22)% | 24 | 28 | (14)% |
| &nbsp;&nbsp;Interest expense | (6) | (7) | (14)% | (18) | (21) | (14)% |
| **Income (loss) before income tax (benefit) expense** | **(24)** | **3** | **(900)%** | **42** | **139** | **(70)%** |
| Income tax (benefit) expense | (4) |  |  | 16 | 39 | (59)% |
| **Net income (loss)** | $**(20)** | $**3** | **(767)%** | $**26** | $**100** | **(74)%** |
| **Net income (loss) per share of common stock** | **Net income (loss) per share of common stock** |  |  |  |  |  |
| &nbsp;&nbsp;Basic | $(0.53) | $0.07 | (857)% | $0.69 | $2.65 | (74)% |
| &nbsp;&nbsp;Diluted | $(0.53) | $0.07 | (857)% | $0.69 | $2.63 | (74)% |

---

____________________________________

<sup>(1)</sup> Revenues are comprised of gross billings less WSEE payroll costs as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
|<br>*(in millions)* | **2025** | **2024** | **2025** | **2024** |
| Gross billings | $10729 | $10291 | $33431 | $32135 |
| Less: WSEE payroll cost | 9106 | 8730 | 28287 | 27167 |
| **Revenues** | $**1623** | $**1561** | $**5144** | $**4968** |

---

------

**SUMMARY FINANCIAL INFORMATION**<br>

**Insperity, Inc.**

**KEY FINANCIAL AND STATISTICAL DATA**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
| | **2025** | **2024** | **Change** | **2025** | **2024** | **Change** |
| **Average WSEEs paid** | 312842 | 309088 | 1% | 309327 | 306650 | 1% |
| **Statistical data** *(per WSEE per month)***:** |  |  |  |  |  |  |
| &nbsp;&nbsp;Revenues<sup>(1)</sup> | $1729 | $1683 | 3% | $1848 | $1800 | 3% |
| &nbsp;&nbsp;Gross profit | 208 | 247 | (16)% | 261 | 302 | (14)% |
| &nbsp;&nbsp;Operating expenses | 235 | 246 | (4)% | 248 | 254 | (2)% |
| &nbsp;&nbsp;Operating income (loss) | (27) | 1 |  | 13 | 48 | (73)% |
| &nbsp;&nbsp;Net income (loss) | (21) | 3 | (800)% | 9 | 36 | (75)% |

---

____________________________________

<sup>(1)</sup> Revenues per WSEE per month are comprised of gross billings per WSEE per month less WSEE payroll costs per WSEE per month as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended <br>September 30,** | **Three Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** | **Nine Months Ended <br>September 30,** |
|<br>*(per WSEE per month)* | **2025** | **2024** | **2025** | **2024** |
| *Gross billings* | $11432 | $11098 | $12009 | $11644 |
| *Less: WSEE payroll cost* | 9703 | 9415 | 10161 | 9844 |
| **Revenues** | $**1729** | $**1683** | $**1848** | $**1800** |

---

------

**NON-GAAP FINANCIAL MEASURES**<br>

**Insperity, Inc.**

**Non-GAAP FINANCIAL MEASURES**

**(Unaudited)**

Non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of the non-GAAP financial measures used to their most directly comparable GAAP financial measures as provided in the tables below.

---

| | | |
|:---|:---|:---|
| **Non-GAAP Measure** | **Definition** | **Benefit of Non-GAAP Measure** |
| Non-bonus payroll cost | Non-bonus payroll cost is a non-GAAP financial measure that excludes the impact of bonus payrolls paid to our WSEEs. | Our management refers to non-bonus payroll cost in analyzing, reporting and forecasting our workers' compensation costs.<br>Bonus payroll cost varies from period to period, but has no direct impact to our ultimate workers' compensation costs under the current program.<br>We include these non-GAAP financial measures because we believe they are useful to investors in allowing for greater transparency related to the costs incurred under our current workers' compensation program. |
| Adjusted cash, cash equivalents and marketable securities | Excludes funds associated with:<br>• federal and state income tax withholdings,<br>• employment taxes,<br>• other payroll deductions, and<br>• client prepayments. | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| | | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| EBITDA | Represents net income computed in accordance with GAAP, plus:<br>• interest expense,<br>• income tax expense,<br>• depreciation and amortization expense, and<br>• amortization of SaaS implementation costs. | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| | | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| Adjusted EBITDA | Represents EBITDA plus:<br>• non-cash stock-based compensation. | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| | | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| Adjusted net income | Represents net income computed in accordance with GAAP, excluding:<br>• non-cash stock-based compensation. | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| | | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| Adjusted EPS | Represents diluted net income per share computed in accordance with GAAP, excluding:<br>• non-cash stock-based compensation. | We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |
| We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |  |  |
| We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior periods, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. Adjusted EBITDA is used by our lenders to assess our leverage and ability to make interest payments. |  |  |

---

------

**NON-GAAP FINANCIAL MEASURES**<br>

Following is a reconciliation of payroll cost (GAAP) to non-bonus payroll costs (non-GAAP):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| *(in millions, except per WSEE per month)* | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| *(in millions, except per WSEE per month)* |  | **Per WSEE** |  | **Per WSEE** |  | **Per WSEE** |  | **Per WSEE** |
| **Payroll cost** | $**9106** | $**9703** | $**8730** | $**9415** | $**28287** | $**10161** | $**27167** | $**9844** |
| Less: Bonus payroll cost | 729 | 777 | 704 | 759 | 3677 | 1321 | 3411 | 1236 |
| **Non-bonus payroll cost** | $**8377** | $**8926** | $**8026** | $**8656** | $**24610** | $**8840** | $**23756** | $**8608** |
| **Payroll cost % change period over period** | **4%** | **3%** | **3%** | **5%** | **4%** | **3%** | **1%** | **3%** |
| **Non-bonus payroll cost % change period over period** | **4%** | **3%** | **—** | **3%** | **4%** | **3%** | **1%** | **3%** |

---

Following is a reconciliation of cash, cash equivalents and marketable securities (GAAP) to adjusted cash, cash equivalents and marketable securities (non-GAAP):

---

| | | |
|:---|:---|:---|
| *(in millions)* | **September 30,<br>2025** | **December 31,<br>2024** |
| **Cash, cash equivalents and marketable securities** | $**440** | $**1055** |
| Less: |  |  |
| &nbsp;&nbsp;Amounts payable for withheld federal and state income taxes, employment taxes and other payroll deductions  | 284 | 830 |
| &nbsp;&nbsp;&nbsp;Client prepayments | 36 | 91 |
| **Adjusted cash, cash equivalents and marketable securities** | $**120** | $**134** |

---

Following is a reconciliation of net income (loss) (GAAP) to EBITDA (non-GAAP) and adjusted EBITDA (non-GAAP):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;*(in millions, except per WSEE per month)* | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| &nbsp;&nbsp;&nbsp;*(in millions, except per WSEE per month)* | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| &nbsp;&nbsp;&nbsp;*(in millions, except per WSEE per month)* |  | **Per WSEE** |  | **Per WSEE** |  | **Per WSEE** |  | **Per WSEE** |
| **Net income (loss)** | $**(20)** | $**(21)** | $**3** | $**3** | $**26** | $**9** | $**100** | $**36** |
| Income tax (benefit) expense | (4) | (4) |  |  | 16 | 7 | 39 | 13 |
| Interest expense | 6 | 6 | 7 | 8 | 18 | 6 | 21 | 8 |
| Amortization of SaaS implementation costs | 1 | 1 | 1 | 1 | 4 | 1 | 7 | 3 |
| Depreciation and amortization | 11 | 12 | 11 | 12 | 33 | 12 | 33 | 12 |
| **EBITDA** | **(6)** | **(6)** | **22** | **24** | **97** | **35** | **200** | **72** |
| Stock-based compensation | 16 | 17 | 17 | 18 | 47 | 17 | 47 | 17 |
| **Adjusted EBITDA** | $**10** | $**11** | $**39** | $**42** | $**144** | $**52** | $**247** | $**89** |
| **Net income (loss) % change period over period** | **(767)%** | **(800)%** | **(93)%** | **(94)%** | **(74)%** | **(75)%** | **(34)%** | **(33)%** |
| **Adjusted EBITDA % change period over period** | **(74)%** | **(74)%** | **(59)%** | **(58)%** | **(42)%** | **(42)%** | **(17)%** | **(16)%** |

---

------

**NON-GAAP FINANCIAL MEASURES**<br>

Following is a reconciliation of net income (loss) (GAAP) to adjusted net income (loss) (non-GAAP):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|<br>*(in millions)* | **2025** | **2024** | **2025** | **2024** |
| **Net income (loss)** | $**(20)** | $**3** | $**26** | $**100** |
| Non-GAAP adjustments: |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation | 16 | 17 | 47 | 47 |
| &nbsp;&nbsp;Tax effect | (4) | (5) | (12) | (13) |
| &nbsp;&nbsp;&nbsp;**Total non-GAAP adjustments, net** | **12** | **12** | **35** | **34** |
| **Adjusted net income (loss)** | $**(8)** | $**15** | $**61** | $**134** |
| **Net income (loss) % change period over period** | **(767)%** | **(93)%** | **(74)%** | **(34)%** |
| **Adjusted net income (loss) % change period over period** | **(153)%** | **(73)%** | **(54)%** | **(27)%** |

---

Following is a reconciliation of diluted EPS (GAAP) to adjusted EPS (non-GAAP):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| *(amounts per share)* | **2025** | **2024** | **2025** | **2024** |
| **Diluted EPS** | $**(0.53)** | $**0.07** | $**0.69** | $**2.63** |
| Non-GAAP adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 0.43 | 0.45 | 1.25 | 1.24 |
| &nbsp;&nbsp;&nbsp;Tax effect | (0.10) | (0.13) | (0.31) | (0.34) |
| **Total non-GAAP adjustments, net** | **0.33** | **0.32** | **0.94** | **0.90** |
| **Adjusted EPS** | $**(0.20)** | $**0.39** | $**1.63** | $**3.53** |
| **Diluted EPS % change period over period** | **(857)%** | **(94)%** | **(74)%** | **(33)%** |
| **Adjusted EPS % change period over period** | **(151)%** | **(73)%** | **(54)%** | **(26)%** |

---

------

**NON-GAAP FINANCIAL MEASURES**<br>

The following is a reconciliation of GAAP to non-GAAP financial measures for fourth quarter and full year 2025 guidance:

---

| | | |
|:---|:---|:---|
|<br>*(in millions, except per share amounts)* | **Q4 2025**<br>**Guidance** | **Full Year 2025**<br>**Guidance** |
| **Net income (loss)** | **$(40) – $(16)**  | **$(15) – $9**  |
| Income tax (benefit) expense | (16) – (6)  | — – 10  |
| Interest expense | 6  | 24  |
| SaaS implementation amortization | 1  | 5  |
| Depreciation and amortization | 10  | 44  |
| **EBITDA** | **(39) – (5)**  | **58 – 92**  |
| Stock-based compensation | 14  | 61  |
| **Adjusted EBITDA** | **$(25) – $9**  | **$119 – $153**  |
| **Diluted EPS** | **$(1.07) – $(0.44)**  | **$(0.38) – $0.25**  |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;Stock-based compensation | 0.37  | 1.62  |
| &nbsp;&nbsp;&nbsp;Tax effect | (0.09) | (0.40) |
| **Total non-GAAP adjustments, net** | **0.28**  | **1.22**  |
| **Adjusted EPS** | **$(0.79) – $(0.16)** | **$0.84 – $1.47**  |

---

<br>